Targeted deletion of BCL11A gene by CRISPR-Cas9 system for fetal hemoglobin reactivation: A promising approach for gene therapy of beta thalassemia disease

Mohammad Ali Khosravi , Maryam Abbasalipour , Jean-Paul Concordet (1) , Johannes Vom Berg , Sirous Zeinali (2) , Arash Arashkia (3) , Kayhan Azadmanesh (4) , Thorsten Buch (5) , Morteza Karimipoor (2)

1 Régulation et dynamique des génomes
2 Biotechnology Research Center
3 Hepatitis & AIDS Dept.
4 Institut Pasteur d'Iran
5 UZH - Universität Zürich [Zürich] = University of Zurich

Domains: Biochemistry, Molecular Biology

Mohammad Ali Khosravi, Maryam Abbasalipour, Jean-Paul Concordet, Johannes Vom Berg, Sirous Zeinali, et al.. Targeted deletion of BCL11A gene by CRISPR-Cas9 system for fetal hemoglobin reactivation: A promising approach for gene therapy of beta thalassemia disease. European Journal of Pharmacology, 2019, 854, pp.398-405. ⟨10.1016/j.ejphar.2019.04.042⟩. ⟨mnhn-02866469⟩